trypsinogen/chymotrypsinogen (PRP) / Propanc Biopharma - LARVOL DELTA

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors (Businesswire) - "Propanc Biopharma, Inc...announced that the Company’s lead asset, PRP, could solve the problem that impacts the response rate of immune checkpoint inhibitors treating PD-L1-High (Programmed Death-Ligand 1) solid tumors, such as lung cancer....Tumor cells that undergo the EMT are motile and invasive, spreading and seeding new tumors, as well as become immortal, no longer dying off naturally. They are also non-dividing, which means they are resistant to standard treatment approaches....A recent study published in the British Journal of Cancer (May, 2024), highlights that EMT induced by tumor cell-intrinsic (i.e., belonging naturally) PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-High lung cancer."

Preclinical • Oncology • Solid Tumor

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office (Businesswire) - "Propanc Biopharma...announced that a Certificate of Grant for the Company’s 'proenzymes composition' patent was received from the Japanese Patent Office. The patent covers dosing regimen claims for the company’s lead asset, PRP, which is advancing to clinical development. This is the fourth Japanese patent either allowed or granted in this important jurisdiction. Also, a certificate of Grant was also received from the Intellectual Property (IP) Corporation of Malaysia for a 'cancer treatment' using therapeutically effective amounts of two proenzymes, trypsinogen and chymotrypsinogen. This is the third granted patent in Malaysia. Currently, the Company’s intellectual property portfolio consists of 93 patents filed in major global jurisdictions relating to the use of PRP against solid tumors....The cancer treatment patent describes a method to target and eradicate cancer stem cells (CSCs) using PRP which minimizes the progression of cancer in a patient."

Patent • Oncology • Solid Tumor

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office (Businesswire) - "Propanc Biopharma, Inc...today announced that a certificate of grant for the Company’s 'composition of proenzymes for cancer treatment,' patent was received from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation. This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company’s IP portfolio growing to 94 patents filed in major global jurisdictions....This PRP dosing patent is an important part of the IP portfolio as it covers possible future clinical dosage ranges for PRP as the Company advances into early-stage clinical development."

Patent • Oncology • Solid Tumor

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study (Businesswire) - N=46 | "Management will provide insights on the remarkable results from the compassionate use study, the steps being undertaken to advance the Company’s lead asset, PRP, to a Phase 1b, First-in-Human (FIH), clinical study, and its future development pathway...members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m....The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel, and melanoma) after treatment with a rectal formulation of pancreatic proenzymes. Nineteen of 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than the expected life span (mean survival of 9.0 months vs life expectancy of 5.6 months), with no severe or serious adverse events related to administration."

Clinical • Clinical data • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office (Businesswire) - "Propanc Biopharma, Inc...today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office. The foundation patent covers composition claims for the Company’s lead product candidate, PRP. In further news, the PRP dosing and method to treat cancer stem cells (CSCs) patents were validated in countries across Europe, resulting in the Company’s IP portfolio growing to 87 patents filed in major global jurisdictions....For the CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs, followed by administering PRP."

Patent • Oncology • Solid Tumor

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities (Businesswire) - "Propanc Biopharma, Inc...today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors. Funds will also be utilized to advance the Company’s back up clinical candidate, Rec-PRP, a synthetic recombinant version of PRP, which will further enhance the potency and stability of the naturally derived proenzyme treatment. As part of the process, the opportunity to consider up-listing to a national US stock exchange will also be considered. The emerging boutique advisory firm currently has a $3B+ transaction history and access to a global network of investors the Company intends to fully utilize."

Financing • Oncology • Solid Tumor

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells (Businesswire) - "Propanc Biopharma, Inc...today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues). The results were reported by the Company’s joint researcher, Mrs. Belén Toledo Cutillas, MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain...It was also proven that a major pathway, TGF-β, responsible for tumorigenesis (production or formation of tumors) and metastasis (cancer spread), is involved with the observed effects by inhibiting this pathway after PRP treatment...PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia (Businesswire) - "Propanc Biopharma, Inc...announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors. Initial discussion held previously with the Clinical Investigator confirmed the remaining development activities to be conducted by the Company prior to filing the clinical trial application for the FIH study."

New trial • Oncology • Solid Tumor

Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030 (Businesswire) - "Propanc Biopharma, Inc...today announced that the Company’s clinical candidate PRP targeting the pancreatic cancer market is forecast to reach $6.93 Billion by 2030, according to a report published by The Brainy Insights, a market research company. According to the report, the global pancreatic cancer market is expected to grow at a compound annual growth rate (CAGR) of 8.13% during the forecast period between 2022 to 2030."

Sales projection • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America (Businesswire) - "Propanc Biopharma, Inc...announced that the Company’s intellectual property (IP) portfolio achieved significant milestones in North America. The foundation patent, covering composition claims for the Company’s lead product candidate, PRP, received a notice of allowance from the Canadian Intellectual Property Office (CIPO). In further news, the Company’s method to treat cancer stem cells (CSCs) using PRP was granted a patent by the United States Patent and Trademark Office (USPTO)....Propanc has an accepted application or achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East and Japan. For the US granted CSCs patent, the claims cover a method to minimize the progression of cancer in a patient who has already received a first line treatment by detecting the presence of CSCs followed by administering PRP."

Patent • Oncology • Solid Tumor

"Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells https://t.co/VKONL2Qxpq" (@NewsFromBW)

Tumor cell • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer (Businesswire) - "Propanc Biopharma, Inc...announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer. Chemotherapy activates certain growth factors, which directly activate cancer-associated fibroblasts (CAFs) to induce collagen deposits in pancreatic ductal adenocarcinoma, thus increasing tumor resistance and becoming unresponsive to treatment, according to Kim, et al., Nature Communications, journal, October 22, 2022."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer (Businesswire) - "Propanc Biopharma, Inc....announced that the Company’s lead product candidate, PRP, could enhance the effects of novel therapies like immune checkpoint inhibitors that can have a role in pancreatic cancer treatment. Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, predicts therapies can enhance the patient’s immune response to fight solid tumors by enabling detection of specific tumor cells within the body that were previously undetected....PRP was recently reported as having a significant impact on the tumor microenvironment by impact inhibiting, slowing, or reversing tumor development through acting as an anti-tumor agent, decreasing tumor cell proliferation, developing a non-malignant phenotype (observable characteristics) and promoting cell adhesion (sticking close to one another) and differentiation (cell specialization rather than stem cell-like)."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17 (Businesswire) - "Propanc Biopharma, Inc...announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, will attend the 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC)...Professor Perán, Propanc’s Lead Joint Researcher, will also be presenting at the annual EORTC-PAMM meeting to be held in Florence, Italy, December 15 – 17....Professor Perán, supported by Mrs. Belén Toledo Cutillas MSc and Mr. Aitor González from Professor Perán’s laboratory at Jaén University will present findings on the anti-cancer effects of the Company’s lead product candidate, PRP, effects on the tumor microenvironment and upscaling of synthetic recombinant protein production for a backup clinical compound for PRP."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

"Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment https://t.co/VP3J1MeUpj" (@NewsFromBW)

Biomarker • Tumor microenvironment • Oncology

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office (Businesswire) - "Propanc Biopharma, Inc...announced that a Notice of Allowance has been received from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer. This is the Company’s second patent application allowed in this jurisdiction and expires in November, 2036. A third patent application is currently under examination at the EPO for a method to treat cancer stem cells, which was allowed in March this year by the US Patent and Trademark Office....The field of the invention covers future dosing in planned clinical studies for the Company’s lead product candidate, PRP. The allowed patent, citing proenzyme compositions to treat cancer, comprising trypsinogen and chymotrypsinogen at specific higher dosage ratios than the Company’s original foundation patent, will enable the Company to cover higher doses in a planned, Phase I, First-In-Human study in advanced cancer patients."

Patent • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients (Businesswire) - "Propanc Biopharma, Inc...announced that...the Company’s lead asset could unlock value as PRP advances to a Phase I, First-In-Human study in advanced cancer patients...the Company conducted several scientific advice meetings with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, to gain an understanding of the regulatory requirements to support a clinical trial application for PRP, to be conducted at the Peter Mac Cancer Center, in Melbourne, Australia. As a result of planning to undertake the first clinical study in Melbourne, Australia, a Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% 'cash back' benefit from overseas R&D expenses...The Company also achieved Orphan Drug Designation Status from the US Food& Drug Administration (FDA) for the treatment of pancreatic cancer..."

New P1 trial • Orphan drug • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use (Businesswire) - "Propanc Biopharma, Inc....announced that the Company is undertaking manufacturing and development of PRP for human use. PRP is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients. It is a long-term therapy for the treatment and prevention of metastatic cancer in patients suffering from solid tumors."

Commercial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

"Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use https://t.co/5vvmtHC1LE" (@NewsFromBW)